Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 487.9m

Basilea Pharmaceutica Future Growth

Future criteria checks 5/6

Basilea Pharmaceutica is forecast to grow earnings and revenue by 20.1% and 6% per annum respectively. EPS is expected to grow by 20.2% per annum. Return on equity is forecast to be 83.8% in 3 years.

Key information

20.1%

Earnings growth rate

20.2%

EPS growth rate

Biotechs earnings growth42.6%
Revenue growth rate6.0%
Future return on equity83.8%
Analyst coverage

Low

Last updated29 Nov 2024

Recent future growth updates

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01
Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24
Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18
If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Earnings and Revenue Growth Forecasts

SWX:BSLN - Analysts future estimates and past financials data (CHF Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262497459583
12/31/20252224654495
12/31/20242056159574
6/30/2024149-1910N/A
3/31/202415351112N/A
12/31/2023158101314N/A
9/30/2023166332022N/A
6/30/2023175562729N/A
3/31/2023161341618N/A
12/31/20221481247N/A
9/30/20221506-21N/A
6/30/20221521-8-5N/A
3/31/2022150-3-20-18N/A
12/31/2021148-7-33-32N/A
9/30/2021130-26-41-40N/A
6/30/2021112-45-50-48N/A
3/31/2021120-30-53-51N/A
12/31/2020128-15-56-54N/A
9/30/2020134-6-55-53N/A
6/30/20201413-53-52N/A
3/31/2020137-10-58-58N/A
12/31/2019134-22-64-64N/A
9/30/2019135-23-64-64N/A
6/30/2019136-24-65-64N/A
3/31/2019134-28-72-72N/A
12/31/2018133-31-80-79N/A
9/30/2018124-26-43-42N/A
6/30/2018115-21-6-5N/A
3/31/2018108-20N/A7N/A
12/31/2017102-19N/A19N/A
9/30/201792-32N/A-19N/A
6/30/201782-44N/A-58N/A
3/31/201774-48N/A-66N/A
12/31/201666-51N/A-75N/A
9/30/201662-55N/A-89N/A
6/30/201658-59N/A-102N/A
3/31/201655-61N/A-85N/A
12/31/201553-62N/A-68N/A
9/30/201550-57N/A-57N/A
6/30/201547-52N/A-46N/A
3/31/201545-47N/A-59N/A
12/31/201442-42N/A-71N/A
9/30/201442-38N/A-71N/A
6/30/201441-35N/A-71N/A
3/31/201441-34N/A-65N/A
12/31/201341-33N/A-59N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: BSLN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BSLN is expected to become profitable in the next 3 years.

Revenue vs Market: BSLN's revenue (6% per year) is forecast to grow faster than the Swiss market (4.2% per year).

High Growth Revenue: BSLN's revenue (6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BSLN's Return on Equity is forecast to be very high in 3 years time (83.8%).


Discover growth companies